Xintela and NorthX Biologics sign collaboration framework agreement

Xintela and NorthX Biologics announce they have signed a collaboration framework agreement to facilitate projects of common interest utilizing their complementary resources and competences in developing and manufacturing Advanced Therapy Medicinal Products (ATMPs). Projects to be initiated under the collaboration framework include product and process development, quality management and expansion capacity for manufacturing ATMPs, among […]

Xintela obtains US patent for stem cell treatment

Xintela announces that the US patent office USPTO has today approved the company’s patent application for treatment of musculoskeletal diseases using Xintela’s stem cell products. The USPTO today issued Xintela’s patent US 11,517,593 covering stem cell treatment of musculoskeletal diseases including osteoarthritis and other degenerative joint diseases as well as treatment of traumatic joint injuries […]

Targinta plans Phase 0 clinical study

Targinta’s Board of Directors has decided to focus development of the company’s therapeutic antibodies on a so-called clinical Phase 0 study (microdosing study) in cancer patients. The purpose of the clinical Phase 0 study is to show, with a very low dose of labeled antibodies, that they target the tumor and thus validate Targinta’s proprietary […]

Xintela starts next dose level of XSTEM in knee osteoarthritis clinical study

Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. The Safety Review Committee for the clinical study assessed the treatment of the eight patients on the lowest XSTEM dose level at the one-month follow-up, concluded the dose […]

Xintela proposes Thomas Eldered as new Board member

Major shareholder in Xintela AB (publ) proposes that the company’s shareholders elect Thomas Eldered as a new member of the Board at the Extra General Meeting on November 28, 2022. The board of directors announces the proposal regarding election of new Board member at the Extra General Meeting on November 28, 2022. The company’s major […]

Xintela completes dosing of XSTEM first dose level in knee osteoarthritis clinical study

Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. All patients at the lowest dose level have now been dosed. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. […]

Xintela starts clinical study with XSTEM for difficult-to-heal leg ulcers

Xintela starts its second clinical study (Phase I/IIa) with XSTEM® for the treatment of difficult-to-heal venous leg ulcers. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. The recruitment of patients for the Phase I/IIa study for the treatment of difficult-to-heal venous leg ulcers, which is carried […]

Targinta presents positive preclinical data on the antibody-drug conjugate TARG9

The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), presents new preclinical data on the antibody-drug conjugate TARG9 at the 2nd Integrin-Targeted Drug Development Summit, Boston, on September 1, 2022 at 11 a.m. local time (17:00 CEST). Targinta develops first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) against the unique and patent protected […]

Targinta obtains patent grant in Japan

The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), announces that the Japanese Patent Office (JPO) has granted a patent covering treatment of tumors of the central nervous system (CNS) using antibodies targeting integrin α10β1. The patent further strengthens Targinta’s intellectual property position and coverage for drug development candidates TARG9 and TARG10. […]